Silexion Therapeutics Stock Forecast

Stock Price Forecast

The 1 analyst with a 12-month price forecast for Silexion Therapeutics stock has a target of 5.00, which predicts a 400.55% increase from the current stock price of 1.00.

Price Target: $5.00 (+400.55%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$5.00	$5.00	$5.00	$5.00
Change	+400.55%	+400.55%	+400.55%	+400.55%

* Price targets were last updated on Mar 20, 2025.

Analyst Ratings

According to 1 stock analyst, the rating for Silexion Therapeutics is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Mar '25	Apr '25	May '25
Strong Buy	1	1	1
Buy	0	0	0
Hold	0	0	0
Sell	0	0	0
Strong Sell	0	0	0
Total	1	1	1

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Naz Rahman Maxim Group	Maxim Group	Strong Buy Maintains $9 → $5	Strong Buy	Maintains	$9 → $5	+400.55%	Mar 20, 2025
Naz Rahman Maxim Group	Maxim Group	Strong Buy Initiates $9	Strong Buy	Initiates	$9	+800.99%	Nov 1, 2024

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

n/a

EPS This Year

-0.98

from -26.36

EPS Next Year

-1.34

from -0.98

Fiscal Year	FY 2012	FY 2013	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2012	Dec 31, 2013	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	-	-	-
Revenue Growth	-	-	-	-	-	-	-
EPS	-65.74	-81.80	-44.23	-26.36	-0.98	-1.34	-1.72
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	3	3	3

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027
High	n/a	n/a	n/a
Avg	n/a	n/a	n/a
Low	n/a	n/a	n/a

Revenue Growth

Revenue Growth	2025	2026	2027
High	-	-	-
Avg	-	-	-
Low	-	-	-

EPS Forecast

EPS	2025	2026	2027
High	-1.01	-1.38	-1.77
Avg	-0.98	-1.34	-1.72
Low	-0.94	-1.28	-1.66

EPS Growth

EPS Growth	2025	2026	2027
High	-	-	-
Avg	-	-	-
Low	-	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.